Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

Category

Giostar News

giocov

GIOSTAR Launches Subsidiary to Combat COVID-19 and Long COVID

Stem cell research institute seeks to ramp up the charge against global pandemic

SAN DIEGO, May 5, 2021 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in regenerative technologies, is pleased to announce the formation of GIOCOV. The company – launched in tandem with TAG Investment Bankers LTD of London (TAG) – is a wholly-owned subsidiary aimed at delivering stem cell-based treatments for the acute phase of COVID-19, along with the chronic phase (known as Long COVID).

A Long Haul for Millions

As of May 2021, roughly 280 million individuals have been fully vaccinated against COVID-19. The worldwide rollout has helped contain the impact and reduce the high morbidity rates of the disease – which has claimed more than 3 million lives. However, data reveals that, even after recovering from COVID-19, many patients continue experiencing a compendium of debilitating symptoms known collectively as Long COVID.

These “long-haulers” may experience one or both of the following:

  • Symptoms experienced throughout the course of COVID-19: fatigue, cognitive impairment (brain fog), difficulty breathing, headaches, difficulty exercising, depression, sleep difficulty, loss of sense of taste or smell
  • New symptoms: hair loss, anxiety, and heart problems

In a study conducted by the Centers for Disease Control (CDC), roughly 1 in 3 patients (including both mild and severe cases) observed suffered from highly debilitating symptoms of COVID-19 several weeks after their diagnosis. Even more alarming, a University of Leicester investigation found that 7 in 10 patients hospitalized for COVID-19 didn’t fully recover 5 months after discharge. These grim statistics point to a dire global health crisis, with enormous projected costs of management.

“Long COVID is very serious,” noted World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus. “To a significant number of people, this virus poses a range of serious long-term effects. The symptoms people have to endure are very debilitating, leading many to be unable to work and function properly.” Long COVID issues may ultimately culminate in chronic disease, requiring sharply increased levels of medication, long-term hospitalization, and debilitating lifestyle changes that will likely lead to premature death.

Extending the Impact of Novel Therapeutic Approach

GIOSTAR has played a central role in the fight against COVID-19. The US Food and Drug Administration (FDA) granted the firm FDA Approval Under Compassionate Use (Expanded Access Program) to treat COVID-19 patients – making GIOSTAR one of the first companies in the world to obtain this credential. Leveraging proprietary scientific protocols and techniques developed by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR succeeded in treating several critically ill COVID patients using stem cells.

“The anti-inflammatory capabilities of stem cells make them an excellent therapeutic agent,” explained Dr. Srivastava. “Further, their ability to differentiate into myriad cells helps to restore organ function, thereby enabling [patient] recovery from the post-COVID-19 syndrome.”

GIOSTAR is looking to build upon its success in addressing the acute phase of COVID-19. With the launch of GIOCOV, the company is now pursuing the fully licensed status of stem cell treatment for COVID and Long COVID patients in the United States (US), United Kingdom (UK), and the European Union (EU). This goal will require completion of clinical trials to establish treatment protocols and secure full approval from FDA, Medicines and Healthcare products Regulatory Agency (MHRA), and European Medicines Agency (EMA) – the regulatory bodies for the US, UK, and EU respectively. Upon receiving this, GIOCOV seeks to gain acceptance from healthcare authorities, providers, and insurers alike for reimbursement of treatment costs.

“GIOCOV’s aim is to provide cost-effective treatment for all Long COVID sufferers worldwide,” noted GIOSTAR CEO and Co-Founder Deven Patel. “This will show huge cost-benefit against the cost of long-term medication and hospitalization and provide enhanced quality of life to patients all over the globe.” Given the results of the aforementioned study, more than 100 million long-haulers (representing 70% of the over 150 million total COVID 19 cases) stand to achieve enormous economic and health-related benefits from this initiative.

To realize these goals GIOSTAR – in collaboration with their advisors TAG Investment Bankers Ltd of London – intends for GIOCOV to raise funds to carry out the necessary trials through a listing on the London Stock Exchange (LSE), Nasdaq, and other stock exchanges. GIOSTAR also aims to secure funding from suitable grants.

GIOSTAR is pleased to officially announce its pre-IPO fundraising round, the details of which are available at the TAG Investment Bankers Website: https://twex.ch/giocov/

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of stem cell science and regenerative medicine. Based in San Diego, California, USA, the company’s primary aim is to develop treatments for the masses suffering from metabolic and degenerative diseases around the globe.

GIOSTAR is a coalition of world-class scientists, physicians, and entrepreneurs in the field of stem cell science. The team members have been involved for the last 20 years in the development and utilization of stem cell-based clinical protocols related to degenerative, malignant, and non-malignant disorders. The adult stem cell technology is well developed and has been used regularly in the Institute’s clinical practice to treat many patients.

Media Contact

Chris Paget
COO at TAG Investment Bankers Ltd
chris.paget@tagbankers.com
Tel: +44 7801 413597

Related Links
https://twex.ch/giocov/
https://www.giostar.com/giocov

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

Promising results point to a potential alternative in combating the pandemic

SAN DIEGO, July 21, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program. As of July 14, 2020, there have been more than 13 million COVID-19 cases and over 500,000 deaths worldwide.

Contending with a Grim Prognosis

Under the direction of GIOSTAR Medical Director Dr. Prabhat Soni, a 53-year old male patient suffering from COVID-19 pneumonia was admitted to Saint Michael’s Medical Center in Newark, New Jersey, under the care of Dr. Richard Miller, MD, Chairman, Department of Pulmonary Medicine. The patient’s condition worsened over the course of the standard treatments, along with convalescent plasma therapy. He went into septic shock and his renal and hepatic functions continued to decline, requiring dialysis. The patient suffered a stroke, and remained in a coma at Saint Michael’s intensive care unit (ICU).

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

Improved Outcomes from an Alternative Strategy

Noting the limited effectiveness of these measures, Dr. Soni designed a plan to treat the patient using stem cells. Research physician Dr. Michael J. DeMarco coordinated the plan, with day-to-day care provided to the patient by Dr. Miller and his Critical Care fellows Dr. Rutwik Patel and Dr. Harish Sharma, at Saint Michael’s.

Following treatment with AlloRx Stem Cells® from Vitro Biopharma, a Colorado-based company, the patient began recovery from multiple organ failure and a coma of almost 7 weeks.  He had excellent recovery of his pulmonary, liver, and renal functions, ultimately coming off dialysis and ventilator support.

The patient’s recovery of neuro-muscular functions is evident in improved clarity of speech, ease of swallowing food, and many other everyday functions. Additionally, the elevated levels of inflammation markers seen prior to stem cell therapy have come down to within normal range. The patient was finally discharged from ICU, and is undergoing physical therapy with strong hopes of complete recovery.

COVID-19 and Mesenchymal Stem Cells (MSCs)

COVID-19 infection leads to uncontrolled release of proinflammatory cytokines – known as “cytokine storms” – that potentially leads to fatal damage of many organs of the body. “MSCs have specific characteristics that, when infused in the bloodstream,” explained Dr. Srivastava, “neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.”

Next Steps for Treatment of COVID-19

“We got outstanding results after using MSCs on our first patient,” noted Dr. Soni, “with similar results being reported by other institutions.” Dr. Srivastava states that “the use of MSCs may be a great option not only for critically ill COVID-19 patients, but also for those who may have risk of exposure. MSCs may prevent people from aggravations of the infection, thereby potentially saving lives while lowering the load on hospitals and the economy.” Drs. Srivastava and Soni emphasize that a placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of stem cell research. Under the leadership of Co-Founders Dr. Anand Srivastava and Mr. Deven Patel, the San Diego-based Institute has a tradition of groundbreaking research in stem cell science spanning over two decades.

 Media contact

Deven Patel
deven@giostar.com

Related Links

https://www.giostar.com/category/news/
https://www.giostarchicago.com/news
https://www.prnewswire.com/news-releases/giostar-reports-on-a-positive-outcome-of-a-covid-19-patient-after-stem-cell-treatment-301100889.html

SAASCR Honors GIOSTAR Chairman Dr Anand – 9 Indian American Scientists Outstanding Cancer Research

GIOSTAR Chairman Receives Award for Outstanding Cancer Research from SAASCR

Organization commemorates a quarter century of leadership in combating intractable diseases

SAN DIEGO, May 4, 2021 /PRNewswire/ —  Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in the field of stem cell science and regenerative medicine, was recently recognized for innovation in cancer research. The Society of American Asian Scientists in Cancer Research (SAASCR) honored GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava with their prestigious Outstanding Achievement Award for 2020. Dr. Srivastava was one of only 10 scientists to receive this accolade, presented at SAASCR’s Annual Meeting on April 11, 2021.

A Novel, Multi-Faceted Approach to Cellular Cancer Immunotherapy
Throughout his illustrious career spanning over twenty-five years, Dr. Srivastava has held positions at prestigious institutions such as University of California San Diego Cancer Center, University of California Irvine, The Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute, and University of California, Los Angeles. Having authored over 100 scientific publications, he has furthered the pursuit toward a cure for cancer – a disease which in 2018 accounted for 9.5 million deaths globally.

Dr. Srivastava’s research culminated in the following essential findings:

  • Mitochondria – organelles that produce energy through oxidative phosphorylation – are very inactive in cancer cells.
  • Re-activated mitochondria facilitate enhanced oxidative phosphorylation, resulting in reversal of cancerous cells into normal cells.

GIOSTAR is developing a three-pronged mechanistic approach to target cancer cells:

  • Utilizing cellular immunotherapy to specifically target tumor cells without damaging healthy ones, thereby minimizing side effects of treatment.
  • Identifying specific nontoxic molecules to block sugar uptake by cancer cells. This limits the nutrient supply needed to meet their increased energy demands.
  • Leveraging enhanced oxidative phosphorylation in cancer cells, which predominantly utilize the glycolytic pathway to produce the energy for their survival.

Extending Global Impact of Stem Cell Research

Under Dr. Srivastava’s leadership, GIOSTAR has accelerated progress toward development of stem cell-based therapies for diseases once considered as incurable. The company has spearheaded numerous recent initiatives including:

  • Receiving FDA Approval for Compassionate Use to treat COVID-19 using stem cells – one of the first institutions to receive this designation.
  • Successfully treating several critically ill patients suffering from COVID-19
  • Launching state-of-the art stem cell clinical facilities in Cancún, Mexico, and Chandigarh, India. The Chandigarh center is focused primarily on cancer research.

Celebrating Noteworthy Achievements of an Active Demographic

SAASCR is a California-based non-profit organization boasting more than 5,000 members – all of whom also share membership in the American Association for Cancer Research. Since its inception in 2004, the society has continuously endeavored to highlight contributions of American Asian scientists in cancer research – including the identification of novel biomarkers, and discovering new drugs for combating cancer.

Other recipients of the 2021 SAASCR Outstanding Achievement Award included researchers from Baylor College of Medicine, The Johns Hopkins University School of Medicine, University of South Florida, National Cancer Institute, National Institutes of Health, and other leading institutions.

“Finding a cure for cancer is an ambitious undertaking,” noted Dr. Srivastava. “I’m therefore quite humbled to be included in this extraordinary community of researchers by SAASCR.”

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of stem cell science and regenerative medicine with the aim to develop treatments for metabolic and degenerative diseases. Headquartered in San Diego, USA, GIOSTAR’s team includes international leaders in the field of stem cell research, technologies, healthcare delivery, and hospital administration.

Related Links

https://www.prnewswire.com/news-releases/giostar-chairman-receives-award-for-outstanding-cancer-research-from-saascr

https://www.giostar.com/saascr-honors-giostar-chairman-dr-anand-9-indian-american-scientists-outstanding-cancer-research/

https://giostarchicago.com/news/

Hollywood star Anna’s review on GIOSTAR skin serum product

Hollywood star Anna’s review on GIOSTAR skin serum product

Hollywood star Anna speaks about issues such as lines like on nose going up towards nose. She further says that she is hard to remain confident when things are definitely wrong. Since using the GIOSTAR skin serum product for 6 weeks, she is now better.

The lines around the eyes and right up to her forehead are getting better since using the product. She is using it on the chest, neck and thanks to the product, she is seeing reversal.

Hollywood star Anna review on GIOSTAR stem cell skin serum

Hollywood star Anna review on GIOSTAR stem cell skin serum

Anna was diagnosed with an autoimmune condition called scleroderma in 2016. Before using GIOSTAR stem cell serum, her jaws were particularly heavy (weird). After using GIOSTAR stem cell serum therapy for 6 weeks she can see the lines diminishing around her eyes, nose.

She noticed tremendous difference especially in the neck, chest. Her other problem is that she tan very easily and get blotchy as she lives near the beach.

Ever since, using the product she can see the elasticity in the skin and blotchiness has faded. By using stem cell, skin serum from GIOSTAR is making a huge difference in the amount of recovery time and her overall appearance.

Hollywood star Anna’s reveals how GIOSTAR stem cell skin serum product improved her appearance

Hollywood star Anna’s reveals how GIOSTAR stem cell skin serum product improved her appearance

Hollywood star Anna talks about how her skin discoloration has reduced. The great thing about the product is that it takes about 3 minutes to do in the morning and 3 minutes at night to see the difference. She using the product for almost 7 weeks but expects to get a baby (soft) skin.

In 7 weeks, she is 80% better and 10 years younger. There is no sagging skin and elasticity is back. The moisture stays all day long and her skin never feels dry and does have bad reactions and with zero side effects.

Make An Inquiry

We are here to help you

WordPress Video Lightbox